Summary of GenomeQuest talk:
Next generation sequencing promises to unlock massive gains in health care productivity, driving efficiencies in pharmaceutical drug development, molecular diagnostics, food production, and ultimately dramatically improving patient care while dropping system-wide health care costs.
As a leading provider of next generation sequencing and analysis services to pharmaceutical companies, molecular diagnostics companies, hospitals, and labs around the world, GenomeQuest is uniquely positioned to provide both solutions for integrating this new technology into life science organizations, as well as perspectives on its use in the industry.
For instance, a pharmaceutical customer of GenomeQuest with an oncology drug already on the market is monitoring a series of adverse events reported by a small population. The FDA is also watching closely. No phenotypic attribution of these adverse events can be made with the post-market data. Engaging GenomeQuest, our customer was able to sequence the genomes of both populations - those reporting adverse events and those reporting no adverse events with high response to the drug. A set of biomarkers were identified through this that is currently driving a simple molecular diagnostic which will be provided by the company as a companion. Nearly $1 billion of revenue will be preserved and patient care will dramatically increase.
In another example, a reference lab for genetic testing for hereditary deafness in the US has provided an expensive DNA-based test to determine whether infants who present with hereditary deafness are candidates for a cochlear implant. Such tests can cost upwards of $50,000, making the test nearly inaccessible for those patients uncovered by health insurance or covered by plans who do not reimburse for the test. Using next generation sequencing and analysis through GenomeQuest's molecular diagnostics software application, the lab is now able to perform the same test for merely $500 - dramatically increasing patient accessibility to a key diagnostic, improving quality of care, and dropping costs by two orders of magnitude.
If your organization doesn't have a next generation sequencing strategy, you are behind the times.
Dr. Jean-Jacques Codani, Chief Scientific Officer, Director and Founder, GenomeQuest
Dr. Codani provides the GenomeQuest's technology vision and direction. For over a decade he has been a leading innovator in the development of the core technologies used to implement GenomeQuest. Prior to his association with GenomeQuest he lead a four year research program on large scale sequence search at the French National Research Institute for Computer Science and Control (INRIA). Before that he was instrumental in developing the computational tools necessary for the physical mapping of the human genome at the Genethon/CEPH.
A single lab can produce in a week as much DNA as the International Databanks Repositories collected for years.The cost of sequencing a single Human Genome has been divided by 1000 in four years. Can this avalanche of data be managed and mined, how and when ? Which impact this technological and economical revolution is having on the Life Science Industry ?
Jean-Christophe Renondin, J.C., M.D., M.B.A., is Managing Director of Bryan, Garnier Bank, with a particular responsibility for life sciences.
http://fr.linkedin.com/in/jcrenondin for more details. JCR was previously with CDC innovation, MDS Capital...Bryan, Garnier & Co is an independent investment banking partnership focused on European growth companies, with offices in London, Paris, New York, and New Dehli. Since 1996, the bank has been specializing in the growth sectors of the economy including the technology-media-telecom, healthcare, renewable energy and environment as well as outsourcing and consumer sectors.